introduction: the protective and antisecretory effects of dopamine agonists on the stomach have been already reported, but the effect of bromocriptine (d2 dopamine agonist) on histamine stimulated gastric acid secretion (gas) needs to be investigated. methods: for gastric sampling, animals were anesthetized and a polyethylen tube was introduced into the stomach through esophagus. a cannula was ...

PURPOSE Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma progression. On the other hand, it is not always effective in clinical application. Although a dopamine D2 receptor deficiency contributes to the impaired efficiency of...

The pattern of androgen dependent enzyme activities of epididymis was studied after the administration of prolactin and bromocriptine in albino rats. Prolactin activated the glycogenolysis and hexose mono and diphosphate pathways, which would be essential for sperm maturation. But bromocriptine inhibited these activities of epididymis. Hence role of bromocriptine in decreasing epididymal functi...

OBJECTIVE To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma. CASE SUMMARY A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in...

OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS A total of 3,095 patients with type 2 diabetes ...

OBJECTIVE In vertebrates, body fat stores and insulin action are controlled by the temporal interaction of circadian neuroendocrine oscillations. Bromocriptine modulates neurotransmitter action in the brain and has been shown to improve glucose tolerance and insulin resistance in animal models of obesity and diabetes. We studied the effect of a quick-release bromocriptine formulation on glucose...

BRomocriptine (15-75 mg per day) alone or with L-dopa was studied during five to 29 months on 44 patients with Parkinson's disease. Used as sole therapeutic agent, it was found excellent in 12 patients who had never received regular L-dopa treatment either because it was never attempted or because of intolerance from the outset. Its anti-Parkinsonism activity was comparable with L-dopa. The gai...

B romocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in a reduction in postmeal plasma glucose ...

due to the prolonged exposure (6 days). hG.H. secretion from another somatotrophic adenoma (data not shown) was inhibited 76-8±2-4% within 24 h by bromocriptine, remained inhibited for 2 days, and subsequently increased in three of four cultures in 24 h when bromocriptine was withdrawn. This change just failed to achieve statistical significance. Further reduction in exposure-time and do...